
    
      COVID-19 patients presenting with acute keratoconjunctivitis will be treated with Topical 1%
      prednisolone acetate fourTimes daily for 7 days as initial treatment, non-preserved
      artificial tears four times daily and cyclosporin A 0.5% four times daily .

      Twelve patients with COVID-19 Keratoconjunctivitis will be enrolled in this open-label study.
      Symptoms and findings of the patients before and after treatment were recorded.
    
  